The Experts below are selected from a list of 115113 Experts worldwide ranked by ideXlab platform
Zaher Fanari - One of the best experts on this subject based on the ideXlab platform.
-
clinical outcomes of the dual therapy CD34 Antibody covered sirolimus eluting stent versus standard drug eluting coronary stents a meta analysis
Cardiovascular Revascularization Medicine, 2020Co-Authors: Paul M Ndunda, Mohinder Vindhyal, Tabitha Muutu, Zaher FanariAbstract:Abstract Background Coronary stent neoatherosclerosis, thrombosis, and restenosis remain significant concerns with new-generation drug-eluting stents (DES). The Dual-Therapy CD34 Antibody-covered sirolimus-eluting stent [dual therapy stent (DTS)] is a sirolimus-eluting stent with CD34 antibodies immobilized on its luminal surface to capture circulating endothelial progenitor cells and promote early endothelialization. We conducted a meta-analysis to determine whether the DTS was superior to standard DES. Methods We conducted a comprehensive search for controlled randomized and non-randomized studies. We presented data using risk ratios (95% confidence intervals) and measured heterogeneity using Higgins' I2. Results Five studies with a low risk of bias met the inclusion criteria, with a total of 1884 patients in the DTS and 1819 in standard DES arms. There was no difference between the 2 arms in the following 1-year outcomes: cardiac death [1% vs 0.9% RR 1.13 (95% CI 0.49–2.62) I2 = 0%], target lesion failure [6.2% vs 5.3% RR 1.12 (0.80–1.58) I2 = 0%], target lesion revascularization (TLR) [4.9% vs 3.4% RR 1.40 (0.93–2.10) I2 = 15%], target vessel failure [8.2% vs 6.1% RR 1.24 (0.75–2.04) I2 = 0%], target vessel myocardial infarction [1.1% vs 1.8% RR 0.73 (0.19–2.90) I2 = 62%] and stent thrombosis [0.4% vs 0.6% HR 0.85 (0.27–2.62) I2 = 0%]. However, compared with second-generation DES (EES and ZES), the DTS had significantly higher one-year TLR [5% vs. 3.1% RR 1.58 (1.02–2.46) P = 0.04 I2 = 0%]. Conclusion One-year TLR was significantly higher in the DTS arm compared with second-generation DES. There was no difference in the other 1-year clinical outcomes compared with standard DES.
-
500 03 clinical outcomes of the dual therapy CD34 Antibody covered sirolimus eluting stent versus standard drug eluting coronary stents a meta analysis
Jacc-cardiovascular Interventions, 2019Co-Authors: Paul M Ndunda, Mohinder Vindhyal, Tabitha Muutu, Sinan Khayyat, Zaher FanariAbstract:Clinical outcomes of drug-eluting stents (DES) in coronary artery disease have improved, but concerns about stent neo-atherosclerosis, thrombosis, and restenosis remain. The COMBO dual therapy stent (COMBO DTS) is a sirolimus-eluting stent with CD34 antibodies immobilized on its surface to capture
Paul M Ndunda - One of the best experts on this subject based on the ideXlab platform.
-
clinical outcomes of the dual therapy CD34 Antibody covered sirolimus eluting stent versus standard drug eluting coronary stents a meta analysis
Cardiovascular Revascularization Medicine, 2020Co-Authors: Paul M Ndunda, Mohinder Vindhyal, Tabitha Muutu, Zaher FanariAbstract:Abstract Background Coronary stent neoatherosclerosis, thrombosis, and restenosis remain significant concerns with new-generation drug-eluting stents (DES). The Dual-Therapy CD34 Antibody-covered sirolimus-eluting stent [dual therapy stent (DTS)] is a sirolimus-eluting stent with CD34 antibodies immobilized on its luminal surface to capture circulating endothelial progenitor cells and promote early endothelialization. We conducted a meta-analysis to determine whether the DTS was superior to standard DES. Methods We conducted a comprehensive search for controlled randomized and non-randomized studies. We presented data using risk ratios (95% confidence intervals) and measured heterogeneity using Higgins' I2. Results Five studies with a low risk of bias met the inclusion criteria, with a total of 1884 patients in the DTS and 1819 in standard DES arms. There was no difference between the 2 arms in the following 1-year outcomes: cardiac death [1% vs 0.9% RR 1.13 (95% CI 0.49–2.62) I2 = 0%], target lesion failure [6.2% vs 5.3% RR 1.12 (0.80–1.58) I2 = 0%], target lesion revascularization (TLR) [4.9% vs 3.4% RR 1.40 (0.93–2.10) I2 = 15%], target vessel failure [8.2% vs 6.1% RR 1.24 (0.75–2.04) I2 = 0%], target vessel myocardial infarction [1.1% vs 1.8% RR 0.73 (0.19–2.90) I2 = 62%] and stent thrombosis [0.4% vs 0.6% HR 0.85 (0.27–2.62) I2 = 0%]. However, compared with second-generation DES (EES and ZES), the DTS had significantly higher one-year TLR [5% vs. 3.1% RR 1.58 (1.02–2.46) P = 0.04 I2 = 0%]. Conclusion One-year TLR was significantly higher in the DTS arm compared with second-generation DES. There was no difference in the other 1-year clinical outcomes compared with standard DES.
-
500 03 clinical outcomes of the dual therapy CD34 Antibody covered sirolimus eluting stent versus standard drug eluting coronary stents a meta analysis
Jacc-cardiovascular Interventions, 2019Co-Authors: Paul M Ndunda, Mohinder Vindhyal, Tabitha Muutu, Sinan Khayyat, Zaher FanariAbstract:Clinical outcomes of drug-eluting stents (DES) in coronary artery disease have improved, but concerns about stent neo-atherosclerosis, thrombosis, and restenosis remain. The COMBO dual therapy stent (COMBO DTS) is a sirolimus-eluting stent with CD34 antibodies immobilized on its surface to capture
Steen Dalby Kristensen - One of the best experts on this subject based on the ideXlab platform.
-
randomized clinical comparison of the dual therapy CD34 Antibody covered sirolimus eluting combo stent with the sirolimus eluting orsiro stent in patients treated with percutaneous coronary intervention the sort out x trial
Circulation, 2021Co-Authors: Lars Jakobsen, Evald Hoj Christiansen, Phillip Freeman, Johnny Kahlert, Karsten Tange Veien, Michael Maeng, Bent Raungaard, Julia Ellert, Anton Boel Villadsen, Steen Dalby KristensenAbstract:Background: Target lesion failure remains an issue with contemporary drug-eluting stents. Thus, the dual-therapy sirolimus-eluting and CD34+ Antibody–coated Combo stent (DTS) was designed to furthe...
-
randomized clinical comparison of the dual therapy CD34 Antibody covered sirolimus eluting combo stent with the sirolimus eluting orsiro stent in patients treated with percutaneous coronary intervention rationale and study design of the scandinavian organization for randomized trials with clinical outcome sort out x trial
American Heart Journal, 2018Co-Authors: Lars Jakobsen, Evald Hoj Christiansen, Michael Maeng, Bent Raungaard, Steen Dalby Kristensen, Hans Erik Botker, Christian Juhl Terkelsen, Morten Madsen, Svend Eggert Jensen, Martin Kirk ChristensenAbstract:Abstract Background The Combo stent (OrbusNeich, Hoevelaken, the Netherlands) combining an abluminal, bioabsorbable polymer eluting sirolimus with a luminal CD34+ Antibody to capture endothelial progenitor cells has been developed to further improve safety and efficacy of coronary interventions. We have designed a large-scale registry-based randomized clinical trial to compare the Combo stent to the Orsiro stent (Biotronik, Bulach, Switzerland) in patients undergoing percutaneous coronary intervention. Methods The SORT OUT X study will randomly assign 3,140 patients to treatment with Combo or Orsiro stents at 3 sites in Western Denmark. Patients are eligible if they are ≥18 years old, have chronic stable coronary artery disease or acute coronary syndromes, and have ≥1 coronary lesion with >50% diameter stenosis requiring treatment with a drug-eluting stent. The primary end point target lesion failure is a composite of cardiac death, myocardial infarction (not related to other than index lesion), or target lesion revascularization within 12 months. Clinically driven event detection will be derived from validated Danish registries. An event rate of 4.2% is assumed in each stent group. With a sample size of 1,570 patients in each treatment arm, a 2-group large-sample normal approximation test of proportions with a 1-sided 5% significance level will have 90% power to detect noninferiority of the Combo stent compared with the Orsiro stent with a predetermined noninferiority margin of 2.1%. Conclusion The SORT OUT X trial will determine whether the dual-therapy Combo stent is noninferior to the Orsiro stent with respect to clinically driven events ( ClinicalTrials.gov NCT03216733 ).
Lars Jakobsen - One of the best experts on this subject based on the ideXlab platform.
-
randomized clinical comparison of the dual therapy CD34 Antibody covered sirolimus eluting combo stent with the sirolimus eluting orsiro stent in patients treated with percutaneous coronary intervention the sort out x trial
Circulation, 2021Co-Authors: Lars Jakobsen, Evald Hoj Christiansen, Phillip Freeman, Johnny Kahlert, Karsten Tange Veien, Michael Maeng, Bent Raungaard, Julia Ellert, Anton Boel Villadsen, Steen Dalby KristensenAbstract:Background: Target lesion failure remains an issue with contemporary drug-eluting stents. Thus, the dual-therapy sirolimus-eluting and CD34+ Antibody–coated Combo stent (DTS) was designed to furthe...
-
randomized clinical comparison of the dual therapy CD34 Antibody covered sirolimus eluting combo stent with the sirolimus eluting orsiro stent in patients treated with percutaneous coronary intervention rationale and study design of the scandinavian organization for randomized trials with clinical outcome sort out x trial
American Heart Journal, 2018Co-Authors: Lars Jakobsen, Evald Hoj Christiansen, Michael Maeng, Bent Raungaard, Steen Dalby Kristensen, Hans Erik Botker, Christian Juhl Terkelsen, Morten Madsen, Svend Eggert Jensen, Martin Kirk ChristensenAbstract:Abstract Background The Combo stent (OrbusNeich, Hoevelaken, the Netherlands) combining an abluminal, bioabsorbable polymer eluting sirolimus with a luminal CD34+ Antibody to capture endothelial progenitor cells has been developed to further improve safety and efficacy of coronary interventions. We have designed a large-scale registry-based randomized clinical trial to compare the Combo stent to the Orsiro stent (Biotronik, Bulach, Switzerland) in patients undergoing percutaneous coronary intervention. Methods The SORT OUT X study will randomly assign 3,140 patients to treatment with Combo or Orsiro stents at 3 sites in Western Denmark. Patients are eligible if they are ≥18 years old, have chronic stable coronary artery disease or acute coronary syndromes, and have ≥1 coronary lesion with >50% diameter stenosis requiring treatment with a drug-eluting stent. The primary end point target lesion failure is a composite of cardiac death, myocardial infarction (not related to other than index lesion), or target lesion revascularization within 12 months. Clinically driven event detection will be derived from validated Danish registries. An event rate of 4.2% is assumed in each stent group. With a sample size of 1,570 patients in each treatment arm, a 2-group large-sample normal approximation test of proportions with a 1-sided 5% significance level will have 90% power to detect noninferiority of the Combo stent compared with the Orsiro stent with a predetermined noninferiority margin of 2.1%. Conclusion The SORT OUT X trial will determine whether the dual-therapy Combo stent is noninferior to the Orsiro stent with respect to clinically driven events ( ClinicalTrials.gov NCT03216733 ).
Mohinder Vindhyal - One of the best experts on this subject based on the ideXlab platform.
-
clinical outcomes of the dual therapy CD34 Antibody covered sirolimus eluting stent versus standard drug eluting coronary stents a meta analysis
Cardiovascular Revascularization Medicine, 2020Co-Authors: Paul M Ndunda, Mohinder Vindhyal, Tabitha Muutu, Zaher FanariAbstract:Abstract Background Coronary stent neoatherosclerosis, thrombosis, and restenosis remain significant concerns with new-generation drug-eluting stents (DES). The Dual-Therapy CD34 Antibody-covered sirolimus-eluting stent [dual therapy stent (DTS)] is a sirolimus-eluting stent with CD34 antibodies immobilized on its luminal surface to capture circulating endothelial progenitor cells and promote early endothelialization. We conducted a meta-analysis to determine whether the DTS was superior to standard DES. Methods We conducted a comprehensive search for controlled randomized and non-randomized studies. We presented data using risk ratios (95% confidence intervals) and measured heterogeneity using Higgins' I2. Results Five studies with a low risk of bias met the inclusion criteria, with a total of 1884 patients in the DTS and 1819 in standard DES arms. There was no difference between the 2 arms in the following 1-year outcomes: cardiac death [1% vs 0.9% RR 1.13 (95% CI 0.49–2.62) I2 = 0%], target lesion failure [6.2% vs 5.3% RR 1.12 (0.80–1.58) I2 = 0%], target lesion revascularization (TLR) [4.9% vs 3.4% RR 1.40 (0.93–2.10) I2 = 15%], target vessel failure [8.2% vs 6.1% RR 1.24 (0.75–2.04) I2 = 0%], target vessel myocardial infarction [1.1% vs 1.8% RR 0.73 (0.19–2.90) I2 = 62%] and stent thrombosis [0.4% vs 0.6% HR 0.85 (0.27–2.62) I2 = 0%]. However, compared with second-generation DES (EES and ZES), the DTS had significantly higher one-year TLR [5% vs. 3.1% RR 1.58 (1.02–2.46) P = 0.04 I2 = 0%]. Conclusion One-year TLR was significantly higher in the DTS arm compared with second-generation DES. There was no difference in the other 1-year clinical outcomes compared with standard DES.
-
500 03 clinical outcomes of the dual therapy CD34 Antibody covered sirolimus eluting stent versus standard drug eluting coronary stents a meta analysis
Jacc-cardiovascular Interventions, 2019Co-Authors: Paul M Ndunda, Mohinder Vindhyal, Tabitha Muutu, Sinan Khayyat, Zaher FanariAbstract:Clinical outcomes of drug-eluting stents (DES) in coronary artery disease have improved, but concerns about stent neo-atherosclerosis, thrombosis, and restenosis remain. The COMBO dual therapy stent (COMBO DTS) is a sirolimus-eluting stent with CD34 antibodies immobilized on its surface to capture